Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRevolution Beauty Regulatory News (REVB)

Share Price Information for Revolution Beauty (REVB)

Share Price is delayed by 15 minutes
Get Live Data
4.65    0.35 (8.14%)
Bid:
4.65
Ask:
4.80
Spread: 0.15 (3.226%)
Market Cap: £40.44m
REVB Live PriceLast checked at - London Stock Exchange

Intraday Revolution Beauty Share Chart

Adam Minto Settlement Agreement

5 Feb 2024 07:00

RNS Number : 9368B
Revolution Beauty Group PLC
05 February 2024
 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For immediate release

5 February 2024

Revolution Beauty Group plc

("Revolution Beauty", the "Group", or the "Company")

Adam Minto Settlement Agreement

Further to the announcement of 13 December 2023, Revolution Beauty (AIM: REVB), the multi-channel mass beauty innovator, is pleased to announce that it has reached a settlement agreement with Adam Minto, the Group's co-founder and former Chief Executive Officer ("CEO").

On 2 February 2024, Revolution Beauty and Adam Minto entered into a settlement agreement (the "Settlement Agreement") relating to the previously announced events that led to the delay of the audit of Revolution Beauty's FY22 results and the suspension of trading of the Group's shares on AIM during Adam Minto's time as CEO, with no admission or acceptance of liability by either party.

Pursuant to the Settlement Agreement, Revolution Beauty and Adam Minto have agreed to the full and final settlement of certain claims between them. In connection with this settlement, Adam Minto will pay Revolution Beauty a settlement sum of £2.9 million (the "Settlement Sum"). The Settlement Sum will be paid in six annual instalments, with the first payment of £483,333.35 due on 28 March 2024 and subsequent equal instalments of £483,333.33 due on 28 March of each calendar year (with the final instalment payable on 28 March 2029). If a Settlement Sum instalment is not paid on time, then interest will be charged at 8% per annum.

Having considered its options and legal advice received, the Board of Directors believe this is a fair settlement for the Company.

Alistair McGeorge, Non-Executive Chairman, commented: "We are very pleased to have reached an agreement with Adam. This, together with the revised payment schedule agreed in December 2023 for the acquisition of Medichem, means we can now focus on the future. We look forward to providing an update on our strategy at our upcoming Capital Markets Event on 8 February 2024".

The signing of the Settlement Agreement constitutes a related party transaction under Rule 13 of the AIM Rules for Companies (the "AIM Rules"), by virtue of Adam Minto being a substantial shareholder, as defined in the AIM Rules, of Revolution Beauty, holding approximately 15.34% of the ordinary shares in Revolution Beauty. The directors of Revolution Beauty consider, having consulted with Revolution Beauty's nominated adviser, Liberum Capital Limited, that the terms of this related party transaction are fair and reasonable insofar as shareholders of Revolution Beauty are concerned.

For further information, please contact:

 

Investor Relations

Lauren Brindley, CEO

Neil Catto, CFO

Investor.Relations@revolutionbeautyplc.com

 

Joint Corporate Brokers

Liberum (NOMAD): Edward Thomas / Dru Danford / John More

Tel: +44 (0) 203 100 2222

 

Zeus: Nick Cowles / Jamie Peel / Jordan Warburton

Tel: +44 (0) 161 831 1512

 

Media enquiries

Headland Consultancy: Matt Denham / Will Smith / Antonia Pollock

Tel: +44 (0)20 3805 4822

Revolutionbeauty@headlandconsultancy.com

 

The person responsible for arranging the release of this announcement on behalf of the Company is Lauren Brindley, the Chief Executive Officer of the Company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRQKBBKDBKBNBK
Date   Source Headline
5th Jun 20267:00 amRNSFinancial Conduct Authority Update
16th Apr 20267:00 amRNSGrant of Share Options
1st Apr 202611:35 amRNSTotal Voting Rights
11th Mar 20267:00 amRNSAppointment of Nominated Adviser
2nd Mar 202611:28 amRNSTotal Voting Rights
3rd Feb 20264:05 pmRNSTotal Voting Rights
3rd Feb 20264:05 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Jan 20263:48 pmRNSTotal Voting Rights
15th Dec 20256:18 pmRNSDirector/PDMR Shareholding
1st Dec 20255:43 pmRNSTotal Voting Rights
27th Nov 20253:59 pmRNSDirector/PDMR Shareholding
27th Nov 20257:00 amRNSInterim Results
26th Nov 20256:15 pmRNSRelated Party Transaction
4th Nov 20254:32 pmRNSTotal Voting Rights
1st Oct 20257:00 amRNSTotal Voting Rights
30th Sep 20259:33 amRNSResult of AGM
24th Sep 20257:00 amRNSDirectorate Change
18th Sep 20257:00 amRNSHolding(s) in Company
17th Sep 202512:30 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSDirector/PDMR Shareholding
16th Sep 20255:17 pmRNSHolding(s) in Company
16th Sep 20259:11 amRNSHolding(s) in Company
11th Sep 20254:09 pmRNSResults of General Meeting
2nd Sep 20258:30 amRNSTotal Voting Rights
1st Sep 20255:06 pmRNSHolding(s) in Company
1st Sep 20258:33 amRNSHolding(s) in Company
29th Aug 20254:50 pmRNSFinal Results, Annual Report Posting & AGM Notice
26th Aug 20257:01 amRNSCircular Publication, Notice of GM & Board Update
26th Aug 20257:00 amRNSResult of Retail Offer to existing shareholders
22nd Aug 20254:31 pmRNSPDMR Dealing
22nd Aug 20253:30 pmRNSHolding(s) in Company
22nd Aug 20258:52 amRNSHolding(s) in Company
22nd Aug 20258:40 amRNSRetail Offer to existing shareholders
22nd Aug 20258:09 amRNSResult of Placing and Subscription
22nd Aug 20257:02 amRNSProposed Placing and Subscription via ABB
22nd Aug 20257:01 amRNSPreliminary Unaudited Results
22nd Aug 20257:00 amRNSTermination of Formal Sale Process
21st Aug 202510:51 amRNSForm 8.5 (EPT/RI)
20th Aug 202510:28 amRNSForm 8.5 (EPT/RI)
19th Aug 202512:27 pmRNSFY25 Trading Update
19th Aug 202510:01 amRNSForm 8.5 (EPT/RI)
18th Aug 202510:27 amRNSForm 8.5 (EPT/RI)
15th Aug 20254:11 pmRNSHolding(s) in Company
15th Aug 20259:57 amRNSForm 8.5 (EPT/RI)
14th Aug 202510:25 amRNSForm 8.5 (EPT/RI)
13th Aug 202510:31 amRNSForm 8.5 (EPT/RI)
12th Aug 202510:05 amRNSForm 8.5 (EPT/RI)
11th Aug 202510:26 amRNSForm 8.5 (EPT/RI)
8th Aug 202511:31 amRNSForm 8.5 (EPT/RI)
7th Aug 20254:26 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.